The SiteRite 9 ultrasound system is a next-generation portable medical device developed by Becton, Dickinson and Company (BD), a medical technology company based in the US.
The system is indicated for vascular, vascular access, interventional, and superficial imaging applications. It can handle a range of specific applications involving peripheral vessel or small organ (including breast, thyroid, parathyroid, and testicles), musculoskeletal (both conventional and superficial), and cardiac imaging for both adults and children.
Recommended White Papers
Recommended Buyers Guides
The SiteRite 9 ultrasound system received the US Food and Drug Administration (FDA) 510(k) approval in September 2023. The medication delivery solutions business of BD Medical launched the system in the US in November 2023.
SiteRite 9 ultrasound system design
The SiteRite 9 system has been entirely redesigned to enhance vascular access, featuring a larger screen, improved image quality, and a more efficient probe connection.
The primary goal of these improvements is to bolster clinician efficiency, particularly during the critical processes of inserting and positioning various vascular access devices. These devices include peripherally inserted central catheters (PICCs), central venous catheters, and intravenous (IV) lines.
SiteRite 9 system details
The system is an all-in-one catheter placement solution designed for a user-friendly experience, featuring an updated 15.6in touchscreen monitor. It is 50% larger than its predicate device SiteRite 8.
The main components of SiteRite 9 include the ultrasound system console, ultrasound beamformer, system software and a linear 25mm ultrasound probe.
It includes the Cue™ needle tracking system, one of the integrated visualisation tools, for continuous and real-time needle tracking and the Sherlock 3CG+™ tip confirmation system (TCS) for proper navigation and location of the catheter tip.
The Cue needle tracking technology offers visual feedback on the needle’s trajectory and tip position relative to the target structure, enhancing the ultrasound-guided needle insertion process and reducing the number of insertion attempts for patients.
The Sherlock 3CG+ TCS is a tip location and confirmation technology primarily designed for vascular access needs.
Additionally, SiteRite 9 is compatible with several accessories, including SiteRite probe cover kits, Pinpoint™ GT needle guide kits, and Site-Rite needle guide kits. Optional accessories include a Sony Printer UP-X898MD, MER roll stand with mounting accessory, kickstand with mounting accessory and a USB storage device.
SiteRite 9 system features
The SiteRite 9 includes advanced connected technology such as vessel assessment tools that automatically identify vessels and work with measurement tools to help clinicians choose the right catheter, ensuring well-informed decisions. Other features include patient data lookup, information capture, auto-fill functions, and record transfer capabilities to enhance clinician workflow.
The system features real-time 2D ultrasound imaging for vascular access device placement, including vessel measurement tools, procedure documentation, vascular access device selection and electronic connectivity.
Clinical applications of SiteRite 9 system
The SiteRite 9 system is used for the assessment of vessels in the extremities from the heart, superficial veins in the arms and legs, and vessel mapping. It is also used for the assessment of superficial thoracic vessels, various superficial assessments of anatomical structures such as breast, parathyroid, thyroid, testicle, lymph nodes and musculoskeletal procedures.
In addition, the system is also used to guide biopsy and drainage.
Marketing commentary on BD
BD works on advancing medical discovery, diagnostics and the delivery of care.
With more than 70,000 employees, the company is dedicated to enhancing the safety and efficiency of clinicians’ care delivery process. It enables scientists to detect diseases accurately and advance their abilities to develop the next era of diagnostics and therapeutics.
BD addresses some of the major global health issues while improving safety, cutting costs and increasing healthcare efficiency by working in close collaboration with customers and partnering with organisations worldwide.
